Cancer drug joins list of medicines in short supply

NewsGuard 100/100 Score
Nov 14 2011

Los Angeles Times: Cancer Drug Doxil Joins Growing List Of Drugs In Short Supply
A crucial cancer drug has been in short supply since midsummer -; and its maker, Johnson & Johnson Inc., has not been able to remedy the situation since. The medicine, Doxil, is used to treat patients with ovarian cancer, multiple myeloma or Kaposi's sarcoma after first-line treatments have failed (Adams, 11/14). 

http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Posted in: Medical Condition News | Pharmaceutical News

Tags: , , , , , , , , ,

Comments (0)

Suggested Reading

New cancer projections show increased prostate cases by 25% in 2050, despite prevention efforts
Breakthrough imaging method enhances precision in prostate cancer treatment
New microfluidic device improves the separation of tumor cells and clusters from malignant effusions
Insilico Medicine's AI-driven approach yields promising PTPN2/N1 inhibitor for cancer immunotherapy
New Lancet Commission on Breast Cancer: Transforming breast cancer care globally
Linking lifestyle to longevity: How diet and hypertension sway risks for heart disease and cancer
New lab assay could make diagnosis and treatment of lung cancer easier
Tiny DNA circles are key drivers of cancer formation, study suggests

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Tumor microbiomes offer new insights for enhancing cancer therapies